Overview

A Phase Ib/IIa Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations

Status:
Recruiting

Trial end date:
2026-07-01

Target enrollment:

Participant gender:

Summary

This is an open label, Phase Ib/IIa study designed to evaluate the safety, toxicity and biological activity of high dose Vitamin C in bone marrow and peripheral blood when administered as therapy to patients with intermediate or high risk myelodysplastic syndrome according to the revised IPSS (international prognostic scoring system) criteria whose disease has a Ten-eleven translocation-2, (TET2) mutation.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

New York University School of Medicine
NYU Langone Health

Collaborator:

Perlmutter Cancer Center

Treatments:

Ascorbic Acid
Vitamins